Study 22143
A Phase 1 Open-label, First-in-human, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Actinium-225-macropa-pelgifatamab (BAY 3546828) in Participants With Advanced Metastatic Castration Resistant Prostate Cancer (mCRPC) Nature and ObjectiveThis Phase 1, first-in-human study investigates the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of actinium-225-macropa-pelgifatamab (BAY3546828) in individuals with advanced metastatic castration-resistant […]
OMAHA-004
MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004) Nature and Objective:This Phase 3 study evaluates the efficacy and safety of opevesostat (MK-5684), a CYP11A1 inhibitor, combined […]
MK-5684-01A Substudy
MK-5684-01A Substudy: A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Nature and Objective:MK-5684-01A substudy aims to evaluate the safety, tolerability, and preliminary efficacy of opevesostat (MK-5684), a CYP11A1 inhibitor, administered alone or in […]
MEVPRO-1
A Phase 3, Randomized, Open-Label Study Of Pf-06821497 (Mevrometostat) In Combination With Enzalutamide Compared With Enzalutamide Or Docetaxel In Participants With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (MEVPRO-1) Nature and Objective:The MEVPRO-1 study investigates the efficacy of mevrometostat (PF-06821497), an oral inhibitor of EZH2, in combination with enzalutamide, in patients with […]
MEVPRO-2
A Phase 3, Randomized, Double Blind, Placebo Controlled Study of PF-06821497 (mevrometostat) with Enzalutamide in Metastatic Castration Resistant Prostate Cancer (MEVPRO-2) Nature and Objective:This Phase I/II open-label, multi-center trial aims to evaluate the safety, tolerability, and anti-tumor activity of [225Ac]Ac-PSMA-R2—a targeted radioligand therapy—in adult men with PSMA-positive metastatic prostate cancer. The study includes patients with […]
SatisfACtion
SatisfACtion: Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With mHSPC and Heavily Pre-treated PSMA-positive mCRPC, With/Without Prior 177Lu-labelled PSMA-targeted Radioligand Therapy. Nature et Objectif:This Phase I/II open-label, multi-center trial aims to evaluate the safety, tolerability, and anti-tumor activity of [225Ac]Ac-PSMA-R2—a targeted radioligand therapy—in adult men with PSMA-positive metastatic prostate cancer. The study includes […]
Pilot project exercise (UQAM)
Optimizing exercise prescription for prostate cancer patients: a pilot study based on participant preferences Nature et objective :A challenge for health professionals is to find adjuvant therapies with a low level of toxicity to combine with standard treatments in order to alleviate the burden of treatment in patients with prostate cancer. Physical activity (PA) is interesting, […]
CAAA617B12203 (PSMACare)
An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and Lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway Inhibitors in patients with PSMA PET scan positive Castration-Resistant Prostate Cancer Nature and objective :The purpose of this study is to evaluate the efficacy and safety of […]
CAAA617A12402 (Phase 4)
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Adult Participants With Prostate Cancer Nature and objective :The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks for lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617. The study also […]
PAnTHA
A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC) Nature and objective :The PAnTHA study aims to assess the safety, tolerance, pharmacokinetics, and preliminary efficacy of 225Ac-PSMA-Trillium, a targeted alpha therapy that is a new class of […]